Literature DB >> 10232833

Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.

M Aviram1, M Rosenblat, S Billecke, J Erogul, R Sorenson, C L Bisgaier, R S Newton, B La Du.   

Abstract

Human serum paraoxonase (PON1) can protect low density lipoprotein (LDL) from oxidation induced by either copper ion or by the free radical generator azo bis amidinopropane hydrochloride (AAPH). During LDL oxidation in both of these systems, a time-dependent inactivation of PON arylesterase activity was observed. Oxidized LDL (Ox-LDL) produced by lipoprotein incubation with either copper ion or with AAPH, indeed inactivated PON arylesterase activity by up to 47% or 58%, respectively. Three possible mechanisms for PON inactivation during LDL oxidation were considered and investigated: copper ion binding to PON, free radical attack on PON, and/or the effect of lipoprotein-associated peroxides on the enzyme. As both residual copper ion and AAPH are present in the Ox-LDL preparations and could independently inactivate the enzyme, the effect of minimally oxidized (Ox-LDL produced by LDL storage in the air) on PON activity was also examined. Oxidized LDL, as well as oxidized palmitoyl arachidonoyl phosphatidylcholine (PAPC), lysophosphatidylcholine (LPC, which is produced during LDL oxidation by phospholipase A2-like activity), and oxidized cholesteryl arachidonate (Ox-CA), were all potent inactivators of PON arylesterase activity (PON activity was inhibited by 35%-61%). PON treatment with Ox-LDL (but not with native LDL), or with oxidized lipids, inhibited its arylesterase activity and also reduced the ability of the enzyme to protect LDL against oxidation. PON Arylesterase activity however was not inhibited when PON was pretreated with the sulfhydryl blocking agent, p-hydroxymercurybenzoate (PHMB). Similarly, on using recombinant PON in which the enzyme's only free sulfhydryl group at the position of cysteine-284 was mutated, no inactivation of the enzyme arylesterase activity by Ox-LDL could be shown. These results suggest that Ox-LDL inactivation of PON involves the interaction of oxidized lipids in Ox-LDL with the PON's free sulfhydryl group. Antioxidants such as the flavonoids glabridin or quercetin, when present during LDL oxidation in the presence of PON, reduced the amount of lipoprotein-associated lipid peroxides and preserved PON activities, including its ability to hydrolyze Ox-LDL cholesteryl linoleate hydroperoxides. We conclude that PON's ability to protect LDL against oxidation is accompanied by inactivation of the enzyme. PON inactivation results from an interaction between the enzyme free sulfhydryl group and oxidized lipids such as oxidized phospholipids, oxidized cholesteryl ester or lysophosphatidylcholine, which are formed during LDL oxidation. The action of antioxidants and PON on LDL during its oxidation can be of special benefit against atherosclerosis since these agents reduce the accumulation of Ox-LDL by a dual effect: i.e. prevention of its formation, and removal of Ox-LDL associated oxidized lipids which are generated during LDL oxidation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10232833     DOI: 10.1016/s0891-5849(98)00272-x

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  120 in total

1.  Serum paraoxonase levels in patients with acute liver disease.

Authors:  C M Bindu; Usha Anand; C V Anand
Journal:  Indian J Clin Biochem       Date:  2011-01-12

Review 2.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

3.  Is there a relationship between serum ox-LDL, oxidative stress, and PON1 in knee osteoarthritis?

Authors:  Cemil Ertürk; Mehmet Akif Altay; Ali Bilge; Hakim Çelik
Journal:  Clin Rheumatol       Date:  2017-06-19       Impact factor: 2.980

4.  Immunobiochemical analysis of Paraoxonase1 (anti-oxidant), xanthine oxidase (oxidant) enzymes and lipid profile of cardiac disease patients in Lahore Metropolitan, Pakistan.

Authors:  Zahoor Qadir Samra; Adeela Sana; Sadia Bano; Mariam Farooq; Nadia Dar; Muhammad Amin Athar
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

5.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

6.  No influence of increased intake of orange and blackcurrant juices and dietary amounts of vitamin E on paraoxonase-1 activity in patients with peripheral arterial disease.

Authors:  Christine Dalgård; Lene Christiansen; Torbjörn Jonung; Michael I Mackness; Moniek P M de Maat; Mogens Hørder
Journal:  Eur J Nutr       Date:  2007-08-21       Impact factor: 5.614

7.  Is alcohol beneficial or harmful for cardioprotection?

Authors:  Raj Lakshman; Mamatha Garige; Maokai Gong; Leslie Leckey; Ravi Varatharajalu; Samir Zakhari
Journal:  Genes Nutr       Date:  2010-06       Impact factor: 5.523

Review 8.  Redox signaling in cardiovascular health and disease.

Authors:  Nageswara R Madamanchi; Marschall S Runge
Journal:  Free Radic Biol Med       Date:  2013-04-11       Impact factor: 7.376

9.  Role of paraoxonase-1 in the protection of hydrogen sulfide-donating sildenafil (ACS6) against homocysteine-induced neurotoxicity.

Authors:  Xiao-Qing Tang; Rong-Qian Chen; Ling Dong; Yan-Kai Ren; Piero Del Soldato; Anna Sparatore; Duan-Fang Liao
Journal:  J Mol Neurosci       Date:  2012-07-29       Impact factor: 3.444

Review 10.  Paraoxonase gene polymorphisms, oxidative stress, and diseases.

Authors:  Hong-Liang Li; De-Pei Liu; Chih-Chuan Liang
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.